Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis.

ABSTRACT:

Objectives

Whether patients with RA benefit from repeated trials of biologic or targeted synthetic DMARDs (b/tsDMARDs) after three or more attempts is unknown. We aimed to describe treatment outcomes in each line of b/tsDMARD therapy.

Methods

Using data from the British Society for Rheumatology Biologics Register for RA from 2001 to 2020, change to a new b/tsDMARD (except biosimilar switches) was defined as a new line of therapy. Treatment outcomes were compared across lines of therapy, including DAS28 remission (≤2.6), low disease activity (LDA, ≤3.2) at 6 months and median time to drug discontinuation. Multiple imputation was used for missing data.

Results

A total of 22 934 individuals starting a first b/tsDMARD were included (mean age 56 years, 76% female), among w

SUBMITTER: Zhao SS 

PROVIDER: S-EPMC9707051 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature